CombiGene and Cell and Gene Therapy Catapult sign agreement to develop manufacturing process for novel gene therapy to treat epilepsy

Jan 12, 2018

Collaboration between Cell and Gene Therapy Catapult (CGT Catapult) and Swedish gene therapy company CombiGene will take a unique therapy one step closer to helping sufferers of hard to treat epilepsy.
Read more >>

Nyheter och rapporter

Panion reports on safety study in dogs – no untoward effects 3 September, 2018
Ingeneious #3 2018, News from CombiGene 3 September, 2018
Kapitalmarknadsdag i Stockholm med flera ledande life science-bolag där också CombiGene deltog 3 September, 2018
CombiGene´s research attracts international attention 29 August, 2018
CombiGene publishes the prospectus for the rights issue 24 August, 2018
CombiGene announces a 75-percent guaranteed preference issue of units amounting to 31 million kronor 22 August, 2018
New research data provide additional support for CombiGene’s gene therapy for difficult-to-treat epilepsy 14 June, 2018
CombiGene participated in a positive meeting with the European Medicines Agency 12 June, 2018
Ingeneious #2 2018, News from CombiGene 4 June, 2018
EU allocates EUR 3.6 million in funding for development of CombiGene’s cuttingedge gene therapy 15 May, 2018
Interim Report January-March 2018 3 May, 2018
Annual Report 2017 2 May, 2018
CombiGene: New issue registered 9 April, 2018
Notice of Annual General Meeting of shareholders in CombiGene AB (publ) 29 March, 2018
Ingeneious #1 2018, News from CombiGene 15 March, 2018
CombiGene: Now we’re strengthening our management team with the addition of Karin Agerman as Chief Research & Development Officer. 13 March, 2018
CombiGene: CombiGene’s issue was subscribed to 22.5 percent 5 March, 2018
All of CombiGene’s board and management will subscribe for shares in the new issue. 22 February, 2018
Final data from long-term study of CombiGene’s epilepsy treatment indicate clearly positive effects in the form of fewer and shorter seizures. 19 February, 2018
CombiGene AB publishes memorandum 12 February, 2018

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"